Is Johnson & Johnson Stock Underperforming the Nasdaq?

New Brunswick, New Jersey-based Johnson & Johnson (JNJ), researches, develops, manufactures, and sells various healthcare products for the consumer, pharmaceutical, and medical devices and diagnostics markets. With a market cap of $362.3 billion, the company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment.

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and JNJ definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the general drug manufacturers industry. The healthcare giant’s focus on high-quality, safe products has earned it a strong reputation among consumers and healthcare professionals. The company's investment in R&D leads to innovative pharmaceuticals and medical devices, keeping it at the forefront of the industry. JNJ's commitment to excellence allows it to penetrate new markets, maintain premium pricing, and stay ahead of market trends.